Here are the latest G-BA decisions from the G-BA meeting held on 5 Dec 2024 on the early benefit assessments of Exblifep and the requirement of RWE collection for marstacimab.
A complete database of all previous G-BA resolutions is in my membership.
- Exblifep (cefepime/enmetazobactam); bacterial infections, multiple indications – Reserve antibiotic; Additional benefit deemed proven across all 3 subgroups
- Marstacimab; haemophilia A and B – No RWE collection; no restriction on prescribing
Follow me on Instagram to never miss the latest G-BA decisions: